CORRECTED-BUZZ-Aeterna Zentaris Inc: Selects Ergomed to conduct late-stage study
(Corrects company name to "Aeterna" from "Aetena" in headline and text)
** Canadian drug developer's U.S.-listed shares up 7.4 pct at $0.29 pre-market
** UK-based drug developer Ergomed PLC will manage late-stage confirmatory study of Aeterna's drug Macrilen, used to evaluate growth hormone deficiency in adults
** Macimorelin, under the trade name Macrilen, has been granted orphan drug designation by the FDA for diagnosis of adult growth hormone deficiency
** Up to Wednesday's close, Aeterna's Toronto-listed stock had declined nearly 72 pct over the last 12 months
© Thomson Reuters 2017 All rights reserved.